iGlyko Technology

Product

iGlyko is committed to the development of a specialized intravenous sensor/catheter and patient monitoring system for blood-glucose measurement of acutely ill, hospitalized patients. iGlyko’s system will reduce medical complications by providing the necessary equipment to maintain tight glycemic control (TGC) at the bedside.

A single-use, disposable sensor/catheter will be inserted into the peripheral vasculature and provide continuous, real-time blood glucose information for several days. iGlyko's system will allow doctors and nurses to continuously monitor glucose level trends, as well as absolute glucose levels, for a wide range of patients beyond those with diabetes, such as mothers in labor and patients undergoing critical operations or procedures. iGlyko's technology will be no more complex in use than a standard IV, and will provide stable, accurate data at a wide range of physiological conditions. Today's burdensome techniques for bedside glucose monitoring will be rendered obsolete, and replaced by this new break-through system.

Technology

iGlyko is developing a new in vivo blood-glucose sensor technology that utilizes a patent-protected, fluorescently-labeled, glucose recognition polypeptide (GRP). GRP is genetically engineered to provide functional features key to developing a state-of-the-art glucose measurement system.

The GRP biosensor binds specifically with glucose and confirms binding with a change in physical shape. This change in physical shape modifies the intensity of the light emitted from the fluorescent label; maximum fluorescence and sensitivity is obtained when there is little glucose present. GRP reversibly binds with glucose without reagents or consumption of glucose, enabling a stable, long-term measurement of glucose.

GRP based sensors are integrated into a fiber-optic IV catheter which resides in a peripheral vein. A light source coupled to the fiber optic sensor excites the fluorescent materials in the GRP. The GRP fluorescent intensity is captured by the fiber-optic catheter and transmitted to the bedside glucose monitor for measurement.

iGlyko, Inc.

Technology